Odetiglucan (1.2 mg, i.v., once a week, 3 weeks) inhibits the proliferation of cancer cells and triggers an effective T cell-mediated response against liver metastases in a mouse model of pancreatic cancer[1].
| Animal Model: | Pancreatic Ductal Adenocarcinoma (PDAC) mouse model[1] |
| Dosage: | 1.2 mg; once a week; 3 weeks |
| Administration: | Intravenous injection (i.v.) |
| Result: | Activated liver-resident macrophages, inhibited cancer cell proliferation, and drived T cell activation and macrophage repolarization in mouse liver metastases. |
